I was pleasantly surprised by how much l learned at the McDermott Will & Emery Life Sciences Deal-making symposium last week. I don’t say that by inferring I know a lot, in quite the opposite, but what I mean is that a lot of conferences and events are the same content but with different names … Continue reading A Recap of the McDermott Will & Emery Life Sciences Deal-making Symposium
Are we in a biotech IPO bubble? Two things have clearly happened over the past few years within this sector. First, pre-money valuation has gone way up, roughly a 130% increase from the 2012-14 period which was a comparably active period to today. Secondly, a larger percentage of companies are Phase II or earlier. That … Continue reading Are We In A Biotech IPO Bubble?
One of the most common questions I get asked comes from Pre-Clinical Life Science companies is why do I need insurance? I agree that pre-clinical life science companies have about as little risk as a company can have. Why they need insurance really comes down to contracts, investors and statutory regulations. If the company enters … Continue reading Common Question Friday – Why Do Pre-Clinical Companies Need Insurance?
Take a listen about what I learned during Boston Biotech Week and the RESI conference. itunes.apple.com/us/podcast/life-sciences-rush-hour-investing-news-risk-management/id1384888594
Every time I read a headline like the one I saw yesterday on the FiercePharma website, “FDA bans products from another Chineses API maker,” I cringe. This is not the first time I have written about these type losses and it won’t be the last as I believe supply chain risk is at or near … Continue reading How to Mitigate Supply Chain Disruption
You may have recently seen that Spineology lost a patent infringement case against Wright Medical. Spineology sued Wright Medical in 2015 for infringing on their patent and the case went back and forth on appeals, finally ending in July of 2018 with Spineology on the losing end. A high-level synopsis can be found here. I … Continue reading How Do You Defend Your Patent?
Cornerstone Research always puts out great data and this report on Securities Class Action Filings for the first half of 2018 is no exception. I recommend you check out the full report which you can find here. These visuals really speak for themselves but the big takeaway is that if you are publicly traded company … Continue reading Why Securities Class Filings are a Reality for Publicly Traded Companies